@article{3aae1dca0eef4229a88ffbdf437e93bd,
title = "Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia",
abstract = "Objectives: Tardive dyskinesia (TD) is a movement disorder that may develop as a side effect of antipsychotic medication. The aetiology underlying TD is unclear, but a number of mechanisms have been proposed. Methods: We investigated single-nucleotide polymorphisms (SNPs) in the genes coding for neuregulin-1 and erbB-4 receptor in our sample of 153 European schizophrenia patients for possible association with TD. Results: We found the ERBB4 rs839523 CC genotype to be associated with risk for TD occurrence and increased severity as measured by the Abnormal Involuntary Movement Scale (AIMS) (P =.003). Conclusions: This study supports a role for the neuregulin signalling pathway in TD, although independent replications are warranted.",
keywords = "Tardive dyskinesia, neuregulin 1 (NRG1), pharmacogenetics, receptor tyrosine-protein kinase erbB-4 (ERBB4), schizophrenia",
author = "Zai, {Clement C.} and Tiwari, {Arun K.} and Chowdhury, {Nabilah I.} and Zeynep Yilmaz and {de Luca}, Vincenzo and M{\"u}ller, {Daniel J.} and Potkin, {Steven G.} and Lieberman, {Jeffrey A.} and Meltzer, {Herbert Y.} and Voineskos, {Aristotle N.} and Gary Remington and Kennedy, {James L.}",
note = "Funding Information: Funding for this study was provided by the Canadian Institutes of Health Research (JLK, VdL, DJM, ANV), Brain and Behavior Research Foundation (CCZ), the Campbell Foundation through the Joanne Murphy Professorship (DJM), and NIH (DJM), Genome Canada (JLK, CCZ, AKT), and Ontario Ministry of Research and Innovation (JLK). We thank the participants in this study. Funding Information: for this study was provided by the Canadian Institute of Health Research (JLK, VdL, DJM, ANV), Brain and Behavior Research Foundation (CCZ), the Campbell Foundation through the Joanne Murphy Professorship (DJM), and NIH (DJM), Genome Canada (JLK, CCZ, AKT), and Ontario Ministry of Research and Innovation (JLK). Funding for this study was provided by the Canadian Institutes of Health Research (JLK, VdL, DJM, ANV), Brain and Behavior Research Foundation (CCZ), the Campbell Foundation through the Joanne Murphy Professorship (DJM), and NIH (DJM), Genome Canada (JLK, CCZ, AKT), and Ontario Ministry of Research and Innovation (JLK). We thank the participants in this study. Funding Information: Funding for this study was provided by the Canadian Institute of Health Research (JLK, VdL, DJM, ANV), Brain and Behavior Research Foundation (CCZ), the Campbell Foundation through the Joanne Murphy Professorship (DJM), and NIH (DJM), Genome Canada (JLK, CCZ, AKT), and Ontario Ministry of Research and Innovation (JLK). Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",
year = "2019",
month = jan,
day = "2",
doi = "10.1080/15622975.2017.1301681",
language = "English (US)",
volume = "20",
pages = "91--95",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Informa Healthcare",
number = "1",
}
